Once Daily vs Twice Daily Administration of Gonadotropins in Assisted Reproductive Technologies (ART) (QD vs BID)

This study has been completed.
Sponsor:
Information provided by:
Virginia Center for Reproductive Medicine
ClinicalTrials.gov Identifier:
NCT00740025
First received: August 21, 2008
Last updated: October 12, 2010
Last verified: October 2010

August 21, 2008
October 12, 2010
January 2006
January 2010   (final data collection date for primary outcome measure)
Ongoing pregnancy [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00740025 on ClinicalTrials.gov Archive Site
peak estradiol, number of follicles, number of oocytes, implantation rate, multiple pregnancy rate [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Once Daily vs Twice Daily Administration of Gonadotropins in Assisted Reproductive Technologies (ART)
A Prospective Randomized Study of QD vs BID Dosing in ART

This is a prospective randomized study evaluating dosing frequency of gonadotropin administration in ART cycles.

Using once daily or bid dosing of gonadotropins in ART has been arbitrary with no studies showing whether splitting the medication dose improves ART parameters. This study was undertaken to provide an answer to this important question.

Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Women between 21-40 yo

Pregnancy
Not Provided
  • QD
    Women who received their meds as QD administration
  • BID
    Women who received their gonadotropins as a BID dose
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
200
January 2010
January 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • women < 40 undergoing ART

Exclusion Criteria:

  • women > 40
  • endometriomas
  • severe cervical stenosis
  • testicular sperm
Female
21 Years to 39 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00740025
1-Sharara
No
Fady I. Sharara, Virginia Center for Reproductive Medicine
Virginia Center for Reproductive Medicine
Not Provided
Principal Investigator: Fady I Sharara, M.D Virginia Center for Reproductive Medicine
Virginia Center for Reproductive Medicine
October 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP